logo

Scynexis, Inc. (SCYX)



Trade SCYX now with
  Date
  Headline
11/13/2018 9:21:38 AM SCYNEXIS Q3 Net Income $0.4 Mln Or $0.01/shr Vs Net Loss Of $8.4 Mln Or $0.31/shr Prior Year
10/23/2018 9:19:43 AM SCYNEXIS Completes End-of-Phase 2 Meeting With FDA For Lead Product Candidate, Ibrexafungerp
10/15/2018 9:28:27 AM SCYNEXIS :First Patient Dosed In Phase 3 Open-label Study Evaluating Oral Ibrexafungerp In Candida Auris Infections
8/22/2018 8:03:37 AM Calyxt Appoints Yves Ribeill As Interim CEO
7/10/2018 4:11:41 PM SCYNEXIS, Trading Expected To Resume At 4:35 PM ET
7/10/2018 4:04:36 PM SCYNEXIS, Trading Halt Pending News
6/27/2018 8:07:01 AM SCYNEXIS Reports Presentation Of SCY-078 Data At Teratology Society 58th Annual Meeting
6/11/2018 8:41:03 AM SCYNEXIS Presents SCY-078 Data At ASM Microbe 2018
4/23/2018 8:24:08 AM SCYNEXIS : Antifungal Activity Against Pneumocystis Supports Potential Use For Prophylaxis Indications
3/6/2018 9:25:53 AM SCYNEXIS Announces Pricing Of $30.0 Mln Public Offering Of Common Stock And Warrants
10/7/2016 7:26:48 AM WBB Securities Lifts SCYNEXIS, Inc. (SCYX) To Strong Buy From Buy With $8 Price Target
11/16/2015 8:50:03 AM RBC Capital Markets Is Lowering SCYNEXIS, Inc. (SCYX) FY17 Estimate To -2.63 From -2.15
11/16/2015 8:49:45 AM RBC Capital Markets Is Cutting SCYNEXIS, Inc. (SCYX) FY16 Estimate To -2.19 From -1.63
11/16/2015 8:49:01 AM RBC Capital Markets Is Lowering SCYNEXIS, Inc. (SCYX) FY15 Estimate To -2.36 From -2.32